PATENT CLAIM ANALYSIS

Application Number: 15864822
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-12
Patent Classification: ["424", "186100"]

Abstract:
The present invention relates, in general, to HIV-1 and, in particular, to broadly neutralizing HIV-1 antibodies, and to HIV-1 immunogens and to methods of using such immunogens to induce the production of broadly neutralizing HIV-1 antibodies in a subject (e.g., a human).

Claim (Index 34):
The composition according to  claim 19 , wherein said composition comprises a purified gp120 HIV-1 envelope protein consisting of all consecutive amino acids immediately after the signal peptide in SEQ ID NO: 884.

Metadata:
- Claim Count in Document: 56.0
- Percentile: 86.0
- Lexical Diversity: 1.75862
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14427581', '15126220', '15559171', '15513539', '14130338']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7756966041961719
- 35 USC 102 Novelty (BERT): 0.7793702181627818
- Combined Prediction Score: 0.7760639655928329
- Mean Citation Score: 614.3696560000002
- Max Citation Score: 1028.8269
- Similarity Product: 921.5903849209784

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test